title: Infection with hepatitis C virus genotype 3--experience of a tertiary health care centre in south India.
abstract: To analyse the response rate and the predictive values of virological, biochemical and histological factors on HCV antiviral therapy in HCV genotype 3 infected patients, we retrospectively studied 21 HCV genotype 3 infected patients, who underwent HCV antiviral therapy. Low (57%) sustained viral response (SVR) rate and significant association of SVR with normalization of alanine transaminase (ALT) levels were observed in our study. Absence of early viral response (EVR) showed high (80%) predictive value on SVR. Absence of EVR and normalisation of the ALT levels can predict the outcome of HCV antiviral therapy.
authors.affiliation: Department of Clinical Virology, Christian Medical College, Vellore - 632 004, India.
authors.forename: J
authors.initials: J
authors.lastname: David
authors.forename: A
authors.initials: A
authors.lastname: Rajasekar
authors.forename: H D D
authors.initials: HD
authors.lastname: Daniel
authors.forename: S L
authors.initials: SL
authors.lastname: Ngui
authors.forename: B
authors.initials: B
authors.lastname: Ramakrishna
authors.forename: U G
authors.initials: UG
authors.lastname: Zachariah
authors.forename: C E
authors.initials: CE
authors.lastname: Eapen
authors.forename: P
authors.initials: P
authors.lastname: Abraham
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics* / Q000302:isolation & purification; D006526:Hepatitis C / Q000188:drug therapy* / Q000473:pathology / Q000821:virology*; D006761:Hospitals; D006801:Humans; D007194:India / Q000453:epidemiology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D000410:Alanine Transaminase; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a